Эффективность профилактики HBV-инфекции у детей с первичным хроническим гломерулонефритом
Диссертация
Корреляция HBsAg-емии у детей, страдающих гломерулонефритом, представленным мембранозной нефропатией, варьирует от 80% в гиперэндемичных регионах (Китай, Африка) до 40−60% в регионах со средней эндемичностью (Италия, Франция). В низкоэндемичных зонах (Северная Европа, Северная Америка, Англия, Австралия) HBV-инфекция определяется у менее 20% больных мембранозной нефропатией. В нашей стране… Читать ещё >
Список литературы
- Бондаренко A. J1. Клинико-иммунопатологический и генетический анализ гепатита В.// Эпидемиология и инфекционные болезни. -1999. -№ 1. -С.42−46
- Длин В.В., Игнатова М.С, Васильева В. И. HBV инфекция у детей с заболеванием почек.// Журнал микробиол., эпидемиол., иммунол. -1993.-№ 4. -С. 108−112
- Зубков М.Л. Вирусные гепатиты. Особенности в условиях заместительной терапии хронической почечной недостаточности (лекция, часть 1).// Нефрология и диализ. -1999. -Т.1. -№ 1. -С.4−11
- Ивашкин В.Т. Комбинированное лечение хронического гепатита В.// Рос. журнал гастроэнтерологии, гепатологии, колопроктологии. -1998. -№ 5. -С.57−66
- Иламанов М.И. Особенности гломерулонефрита у детей с НВ- и дельта-вирусной инфекцией.// Автореферат дисс.. д.м.н. -1998 г. -С.48
- Кагачов Б.С. Вирусный гепатит В: достижения и проблемы.// Рос. педиатр, журнал. -1998. -№ 1. -С.50−60
- Косминова Е.Н. Особенности поражения почек при хронических диффузных заболеваниях печени, обусловленных вирусом гепатита В.// Автореферат дисс.. к.м.н. -1992 г. -С.21
- Катышева О.В., Новикова А. В., Длин В. В. и др. Вирусные антигены, выявленные при биопсии почки, у детей с гл ом еру л о н еф р и том. // Вопросы вирусологии. -1995. -№ 2. -С.35−39
- Кетлинский С.А., Калинина Н. М. Цитокины мононуклеарных фагоцитов в регуляции реакции воспаления и иммунитета.// Иммунология.-1995. -№ 3. -С.30−44
- Лобзин Ю.В., Жданов К. В. Этиотропная терапия гепатитов В, D и С.// Эпидемиология и инфекционные болезни. -1997. -№ 6. -С.42−47
- Наумова В.И., Иламанов М., Иванов В. Г. Вирусный гепатит В и первичный гломерулонефрит у детей.// Педиатрия. -1991. -№.7. -С.57−62
- Новоженов В.Г., Селькова Е. П., Кожокарь Ю. В. и др. Современные аспекты профилактики гепатита В в центрах гемодиализа.// Военно-мед. жур. -2000. -№ 4. -С.56−61
- Поляков А.П. Инфекция вирусом гепатита В: перспективы лечения.// Клиническая фармакология и терапия. -1999. -Т.8. -№ 1. -С.78−82
- Серов В.В., Мухин Н. А. Иммунопатология хронических вир>сьых заболеваний печени.// Вестник РАМН. -2000. -№ 11. -С.44−47
- Скачкова Л.О. Вакцинопрофилактика вирусного гепатита В у детей с тяжелой соматической патологией.// Автореферат дисс.. к.м.н. -2000 г. -С.24
- Сторожаков Г. И., Никитин И. Г. Хронические вирусные заболевания печени системные инфекции?//Тер. архив. -1998. -№ 2. -С.80−82
- Студеникин М.Я., Наумова В. И., Гнаткж А. И. и др. Классификация гломерулонефрита у детей.// Педиатрия,-1977. -№ 2. -С.3−8
- Таточенко В.К. Современные проблемы вакцинации.// Рос. педиатр, журнал. -2000. -№ 5. -С.23−25
- Титов И.А. Характеристика вакцин против вирусного гепатита В и их использование в календаре прививок.// Автореферат дисс.. к.м.н. -1998 г. -С.36
- Фрейдлин И.С. Ключевая позиция макрофагов в цитокиновой регуляторной сети.// Иммунология. -1995. -№ 3. -С.44−48
- Цыгин А.Н. Патогенетические основы первичного нефротического синдрома и лечения его стероидрезистентных вариантов у детей.// Автореферат дисс.. д.м.н. -1996 г. -С.42
- Цыгин А.Н., Сенцова Т. Б., Сергеева Т. В. и др. Уровень растворимого рецептора к интерлейкину-2 и фактора некроза опухоли-а в сыворотке крови детей с нефротическим синдромом.// Педиатрия. -1997. -№ 2. -С.53−56
- Цыгиь А.Н., Сергеева Т. В. Лечение гломерулонефрита у детей.// Рус. мед. журнал. -1998. -Т.6. -№ 9. -С.580−585
- Ярилин А.А. Система цитокинов и принципы ее функционирования в норме и при патологии.// Иммунология. -1997. -№ 5. -С.7−14
- Agarwal S.K., Irshad М. Comparison of two schedules of hepat. tis В vaccination in patients with mild moderate and severe renal failure.// J. Assoc. Physicians India. -1999. -Vol.47. -№ 2. -P. 183−185
- Ai-Wakeel J., Mitwall A., Tarf N. et al. Role of interferon-alpha in the treatment of primary glomerulonephritis.// Am. J. Kidney Dis. -1999. -№ 6. -P.l 142−1146
- Allen M.I., Deslauriers M., Andrews C.W. et al. Identification and characterization of mutations in hepatitis В virus resistant to lamivudine.// Hepatology. -1998. -Vol.27. -P. 1670−1677
- Anandh U., Bastani В., Ballal S. Hepatitis В vaccination in maintenance hemodialysis patients.// Am. J. Nephrol. -2000. -Vol.20. -№ 1. -P.53−56
- Banatvala J., Van Damme P., Oehen S. et al. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.// Vaccine. -2000. Vol.19. -№ 7−8. -P.877−885
- Bhimma R., Coovadia HM, Kramvis A. et al. HBV and proteinuria in relatives and containes of children with hepatitis В virus-associated membranous nephropathy.// Kidney-Int. -1999. -Vol.55. -№ 6. -P.2440−2449
- Bock G.H., Ongkingco JR., Patterson L.T., Ruley J. et al. Serum and urine soluble interleukin-2 receptor in idiopathic nephrotic syndrome.// Pediatr. Nephrol. -1993. -Vol.7. -№ 5. -P.523−528
- Bonino F" Oliveri F., Colombatto P. Хронические гепатиты В и С: современные достижения науки и практики.// Рос. журнал гастроэнтерологии, гепатологии. -1994. -№ 2. -С.30−35
- Bertoletti A., Maini М. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis В and С infection?// Curr-Opin-Microbiol. -2000. -Vol.3. -№ 4. -P.387−392
- Carreno V., Marcellin P., Hadziyannis S. et al. Retreatment of chronic hepatitis В antigen-positive patients with recombinant alpha-2a-interferen.// Hepatology. -1999. -Vol.30. -№ 1. -P.277−282
- Chang T.T., Lai Y.F. Leung N.W. et al. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine.// Hepatology. -1999. -Vol.30 -420A
- Chang T.T., Lai C.L. Liaw Y.F. et a! Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years.// Antiviral. Ther. -2000. -Vol.5.-Supp 11. -P.44
- Chiaramonte M., Majori S., Ngatchu T. et al. Two different dosages of yeast-derived recombinant hepatites В vaccines: a comparison of immunogenicity.// Vaccine. -1996. -Vol.14. -P. 135−137
- Chien R.N., Liaw Y.F., Atkins M. et al. Pretherapy alanine transaminase level as determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis В.// Hepatology. -1999. -Vol.30. -P.770−774
- Chrul S" Zochniak K., Zochniak J. et al. CD3-CD25 lymphocyte population and blood serum 1L-2R in children with liponephrosis.// Pol. Merkuriusz. Lek.-2000. -Vol.8. -№ 46. -P.214−215
- Chung D.R., Yang W.S., Kim S.B. et al. Treatment of hepatitis В virus-associated glomerulonephritis with recombinant human alpha interferon.// Am. J.Nephrol. -1997. -Vol.17. -P.l 12−117
- Combes В., Stastny P., Shorey J. et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane.// Lancet. -1971. -Vol.11. -P.234−237
- Conjeevaram H.S., Hoofnagle J.H., Austin H.A. et al. Long-term outcome of hepatitis В vims-related glomerulonephritis after therapy with alpha-interferon.//Gastroenterology. -1995. -Vol.109. -P.540−546
- Coovadia H.M., Adhikari M., Moodley D. Hepatitis Bs and Be antigen carriage in children nephrotic syndrom predicts membranous glomerulonephritis.// Ann. Trop. Pediatr. -1993. -Vol.13. -№ 1. -P.79−82
- Crovari P., Cuneo-Crovari P., Icardi G.C. Immunization of young adults with two yeast-derived hepatitis В vaccines.// Zuckerman Am J. -1988. -P. 1071−1073
- Dacko C., Holley J.L. The influence of nutritional status, dialysis adequecy, and residual renal function on the response to hepatitis В vaccination in peritoneal dialysis patients.// Adv. Perit. Dial. -1996. Vol.12. -P.315−317
- Daniel V., Trautmann Y., Konrad M., Nayir A. et al. T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. // Clin. Nephrol. -1997. -Vol.47. -№ 5. P.289−297
- Da Silva L" da Fonseca L. Predective factors of response to lamivudine in chronic hepatitis B.// Rey. Inst. Med. Trop. San-Paulo. -2000. -Vol.42. -№ 4. -P. 189−96
- Dahl-Hansen E" Siebke J.C., Froland S.S. et al. Immunogenicity of yeast-derived hepatitis В vaccine from two different pioducers.// Epidemiol. Infect. -1990. -Vol.104. -P. 143−149
- Dhiman R.K., Kohli H.S., Das G. et al. Remission of HBV related mesangioproliferative glomerulonephritis after interferon therapy.// Nephrol. Dial. Transplant. -1999. -Vol.14. -№ 1. -P.176−178
- Di-Bisceglie A.M. Long-term outcome of interferon-alpha therapy for chronic hepatitis B.// J. Hepatol. -1995. -Vol.22. -Suppl.l. -P.65−67
- Dienstag J.L., Schiff E.R., Wright T.L. et al. Lamivudine as initial treatment for chronic hepatitis В in the United States.// N. Engl. J. Med. -1999. -Vol.341. -№ 17. -P. 1256−1263
- Dilek K., Dilek S., Ersoy A. et al. Factors influencing response to hepa’itis В vaccination of haemodialysis patients and timing of additional booster doses.// 34th Congress ERA-EDTA. Geneva. -1997
- Dimitrov Y" Heibel F., Marcellin L. et. al. Acute renal failure and nephrotic syndrome with alpha interferon.// Nephrol. Dial. Transplant. -1997. -№>12. -P.200−203
- Dixon J.S., Boehme R.E. Lamivudine for the treatment of chronic hepatitis В.// Acta-Gastroenterol-Belg. -2000. -Vol.63. -№ 4. -P.348−356
- Farrell G.C. Clinical potential of emerging new agents in hepatitis B.// Drugs. -2000. -Vol.60. -№ 4. -P.701−710
- Fattovich G., Farci P., Rugge M. et. al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis В lacking HBeAg.// Hepatology. -1992. -Vol.15. -P.584 589
- Fraser G.M., Ochana N., Fenyves D. Increasing serum creatinine and age reduce the response to hepatitis В vaccine in renal failure patients.// J. Hepatol. -1994. -Vol.21. -№ 3. -P.450−454
- Furth S.L., Neu A.M., Sullivan E.K. et al. Immunization practices in children with renal disease: a report of the North American Pediatric Renal Transplant Cooperative Study.// Pediatr. Nephrol. -1997. -Vol.11. -P.443−446
- Garcia L., Asensi A.A., Coli E. Anti-HBs titers after a vaccination program in children and adolescents. Shoulds a booster dose be given.// An. Esp. Pediatr. -2001. -Vol.54. -№ 1. -P.32−37
- Garin E.H. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome.// Pediatr. Nephrol. -2000. Vol.14. — № 8−9. — P.872−878
- Germana V., Mowat G. P., Mowat A.P. Viral hepatitis in children with renal disease.// Pediatr. Nephrol. -1994. -Vol.8. -P.610−619
- Gilbert R.D., Wiggelinkhuizen J. The clinical course of hepatitis В virus-associated nephropathy.// Nephrol. Dial. Transplant. -1999. -Vol.14. -P. 176−178
- Gilbert R.D., Wiggelinkhuizen J. The clinical course of hepatitis В virus-associated nephropathy.// Pediatr. Nephrol. -1994. -Vol.8. -№ 1. -P.l 1−14
- Goeser I. Chronic hepatitis В virus infection and interferon-alpha.// Nephrol. Dial. Transplant. -1995. -Vol.10. -№ 10. -P.1793−1794
- Gonzalo A., Mampaso F., Barcena R. et al. Membranous nephropathy associated with hepatitis В virus infection: long-term clinical and histological outcome.// Nephrol. Dial. Transplant. -1999. -Vol.14. -P.416−418
- Grzesiowski P., Tanska A., Sieniawska M. The influence of hepatitis В vaccine dose on direct results of hepatitis В vaccination in children with nephrotic syndrome.// Pediatr-Pol. -1995. -Vol. 70. -№ 1. -P.25−28
- Grzesiowski P., Ziolkowska H., Sobolewska-Wojciechowska B. et al. Long-term efficacy of hepatitis В vaccine in children with chronic renal failure.// Pediatr-Pol. -1995. -Vol. 70. -№ 5. -P.401−405
- Guidotti J.G., Ishikawa Т., Hobbs M.V. et al. Intracellular inactivation of the hepatitis В virus by cytotoxic T lymphocytes.// Immunity. -1996. -№ 4. -P.35−36
- Gust I.D. Epidemiology t patitis В infection in the Western Pacific and South East Asia.// Gut. -1996. -Vol.>8. -Suppl.2. -S. 18−23
- Hail A.J. Hepatitis В vaccination: protection for how long and against what?// BMJ. -1993. -Vol.307. -P.176−177
- Hartmann H. Extrahepatic manifestations of HBV anu v infection.// Schweiz Rundsch Med Prax. -1997. -Vol.86. -№ 29−30. -P.l 163−1166
- Haubitz M., Ehlerding G., Beigel A. et al. Clinical experience with a new recombinant hepatitis-B vaccine in previous non-responders with chronic renal insufficiency.//Clin. Nephrol. -1996. -Vol.45. -№ 3. -P. 180−182
- He X.Y., Fang L.I., Zhang Y.E. et al. In situ hybridization of hepatitis В DNA in hepatitis B-associated glomerulonephritis.// Pediatr. Nephrol.-1998. -Vol.12. -№ 2. -P.l 17−120
- Heijtink R.A., Janssen H.L. Interferon therap-, in chronic hepatitis B: early monitoring of hepatitis В antigen may help to decide whether to stop or to prolong therapy.//J. Viral. Hepat. -2000. -Vol.77. -№ 5. -P.382−386
- Hess G" Kreiter F., Kosters W. Deusch K. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis В vaccination in haemodialysis patients.//J. Vir. Hepat. -1996. -Vol.3. P. 149−153
- Heslan JM., Branellec Al., Pilatte Y. et al. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome.// Clin. Exp. Immunol.-1991.-Vol.86.-№ 1.-P. 157−162
- Hulton S.A., Shah V., Byrne M.R., Morgan G. et al. Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome.// Pediatr. Nephrol. -1994. -Vol.8. -№ 2. -P. 135−139
- Hunt C.M., McGill J.M., Allen M.Y. et al. Clinical relevans of hepatitis В viral mutations.// Hepatology. -2000. -Vol.31. -№ 5. -P. 1037−1044
- Islek I., Cengiz K., Cakir M. et al. Nephrotic syndrome follow hepatitis В vaccination.// Pediatr. Nephrol. -2000. -Vol.14. -P.89−90
- Jilg W., Schmide M., Deinharde F. et al. Persistence of specific antibodies after hepatitis В vaccination.//J. Hepatol. -1988. -Vol.6. -P.201−207
- Johnson D.W., Fleming S.J. The use of vaccines in renal failure.// Clin. Pharmacocinet. -1992. -Vol.22. -№ 6. -P.434−446
- Jonson M., Jennkine J. A study the pharmacokinetic interaction between lamivudine and alfa-interferon.// Eur. J. Clin. -2000. -Vol.56. -№ 4. -P.289−292
- Jung M., Diepolder H., Pape G.R. et al. T cell recognition of hepatitis В and С viral antigens.// Eur. J. Clin. Invest. -1994. -№ 24. -P.641−650
- Jungers P., Chauveau P., Courouce A.M. et al. Recombinant vaccine and extracting vaccine against hepatitis В in patients with kidney insufficiency: comparative immunogenicity.// Press. Med. -1994. -Vol.23. -№ 6. -P.277−280
- Jungers P., Chauveau P., Courouce A.M. et al. Immunogenicity of the recombinant GenHevac В Pasteur vaccine against hepatitis В in chronic uremic patients.// J. Infect. Dis. -1994. -Vol.169. -№ 2. -P.399−402
- Jungers P., Devillier P., Salomon H. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis В vaccine.// Lancet. -1994. -Vol.344. -№ 8926. -P.856−857
- Kapoor D., Aggarwal S.R. Singh N.P. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis В virus vaccine in previously unvaccinated haemodialysis patients.// J. Viral. Hepat. -1999. -Vol. 6. -№ 5. -P.405−409
- Kayats M., Akalin E., Ozdemir F.N. et al. Levamisole treatment enhances protective antibody response to hepatitis В virus vaccination (HBVV).// 34th Congress ERA-EDTA. Geneva. -1997. -P. 173
- Kohler H. Hepatitis В immunisation in dialysis patients is it worthwhile.// Nephrol. Dial. Transplant. -1994. -Vol.9. -P.1719−1720
- Kohler H., Meuer S.C. Eftects of interleukin-2 on hepatitis В vaccination in uraemic patients.//Lancet. -1994. -Vol.344. -№ 8933. -P. 1368−1369
- Krane N., Gaglio P. Viral hepatitis as a cause of disease.// South Med. J. -1999. -Vol.92. -№ 4. -P.354−360
- Lai C.L., Chien R.N., Leung N.W. et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.// N. Engl. J. Med. -1998. -Vol.339. -P.61−68
- Lai F.M., Lai R.N., Tam J.S. Primary glomerulonephritis with detectable glomerular hepatitis В virus antigen.// Am. J. Surg. Pathol. -1994. -Vol.18. -№ 2. -P.175−186
- Lai F.M., To K.F., Wang A.Y. et al. Hepatitis В virus-related nephropathy and lupus nephritis: morphologic similarities of two clinical entities.// Med-Pathal. -2000. -Vol.13. -№ 2. -P. 166−172
- Lai K.N., Ho R.T., Tarn J.S. et al. Detection of hepatitis В virus DNA and RNA in kidneys of HBV related glomerulonephritis.// Kidney-Int. -1996. -Vol.50. -№ 6. -P. 1965−1977
- Lai K.N., Jam J.S., Lin H.J. et al. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis В virus surface antigeneniia.// Nephron. -1990. -Vol.54. -P. 12−17
- KM. La-Manna A., Polito C., Foglia A.C. et al. Reduced response to hepatitis В virus vaccination in boys with steroid-sensitive nephrotic syndrome.// Pediatr. Nephrol. -1992. -Vol. 6. -№ 3. -P.251−253
- La Manna A., Polito C., Foglia A.C. et al. Normal response to anti-HBV vaccination in children with chronic renal insufficiency.// Child Nephrol. Urol. -1991. -Vol.11. -P 203−205
- Levy M., Chen N. Worldwide perspective of hepatitis В associated glomerulonephritis in the 80s.// Kidney-lnt. -1991 .-Vol.35. -P.24−33
- Liaw Y.F., Leung N.W., Chang T.T. et al. Effects of extended lamivudine therapy in Asian patients chronic hepatitis B.// Gastroenterology. -2000. -Vol.119. -P. 172−180
- Lin C.Y. Clinical features and natural course of HBV-related glomerulopathy in children.// Kidney Int. -1991. Vol.35. -P.46−53
- Lin C.Y. Hepatitis В virus dizoxyribonucleic acidin kidney cells probably leading to viral pathogenesis among hepatitis В virus associated membranous nephropathy patients.// Nephron. -1993. -Vol.63. -№ 1. -P.58−64
- Lin C.Y. Treatment of hepatitis В virus-associated membranous nephropathy with recombinant alpha interferon.// Kidney Int. -1995. -Vol.47. -P.225−230
- Lin C.Y., Lin C.C., Chang G.J. et al. Defect of cell-mediated immune response against hepatitis В virus: an indication for pathogenesis of В virus-associated membranous nephropathy.// Nephron. -1997. -Vol.76. -№ 2. -P. 176−185
- Lok A.S. Hepatitis В infection: pathogenesis and management.// J. Hepatol. -2000. -Vol.32. -Suppl. 1. -P.89−97
- Luscombe C. A., Locarnini S. A. The mechanism of antiviral agents in chronic hepatitis В.// Viral Hepatitis Review. -1996. -Vol.2. -№ 1. -P. 1−35
- Macario K, Freitas I., Correria J. et a'. Nephrotic syndrome after recombinant hepatitis В vaccine. -1995. -Vol.43. -P.349
- Maddrey W.C. Hepatitis В an important public health issue.// Clin. Lab. -2001. -Vo!.47. -№ 4. -P.51−55
- Malaguarnera M" Restuccia S., Ferlito L. et al. Evidance-based medicine treatment of chronic virus hepatitis В.// An. Med. Interna. -2000. -V.17 -№ 12. -P.660−664
- Mandreoli M., Beltrandi E., Casadei M. et al. Lymphocyte release of soli Die IL-2 receptors in patients with minimal change nephropathy.// Clin. Nephrol. -1992. -Vol.37. -№ 4. -P. 177−182
- Marangi A.L. Giordano R. Montanaro A. et al. A successful two-step integrated protocol of anti-HBV vaccination in chronic uremia.// Nephron. -1992. -Vol. 61. -№ 3. -P.331−332
- Marangi A.L., Giordano R. Montanaro A. et al. Hepatitis В virus infection in chronic uremia: long-term follow-up of two-step integrated protocol of vaccination.// Amer. J. Kidney Dis. -1994. -Vol.23. -P.537−542
- Mauri J.M. Valles M. Effects of recombinant interleukin-2 and revaccination for hepatitis В in previously vaccinated, non-responder, chronic uraemic patients.// Nephrol. Dial. TranspL. a 1997. -Vol.12. -№ 4. -P.729−732
- Mazzelia G., Saracco G., Li P.K. Long-term resulta with interferon therapy in chronic hepatitis B: prospective randomized trial.// Am. J. Gastroenterol. -1999. -Vol.94. -№ 8. -P.2246−2250
- McQuillan GM" Coleman PJ., Kruszon-Moran D. et al. Prevalence of hepatitis В virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994.// Am. J. Pub. Health. -1999. -Vol.89. -P. 14−18
- Melegari M., Scaglioni P.P., Wands J.R. et al. Hepatitis В virus mutants associated with 3TC and famciclovir administration are replication defective.// Hepatology. -1998. -Vol.27. -P.628−633
- Mettang Т., Schenk U., Thomas S. et al. Low-dose intradermal versus intramuscular hepatitis В vaccination in patients with end-stage renal failure. A preliminary study.// Nephron. -1996. Vol.72. -№ 2. -P. 192−196
- Meuer S.C., Dumann H., Kohler H. Low-dose interleukin-2 induces systemic immune responses against HbsAg in immunodeficient non-responders to hepatitis В vaccination.// Lancet. -1989. -Vol.1. P. 15−18
- Moradpour D., Wands J.R. Understanding В virus infection.// N. Engl. J. Med. -1995. -№ 332. -P. 1092−1093
- Morgan D.R. A code of practice for implementation of the UK hepatitis В immunisation guidelines for the protection of patients and staff.// London. British Medical Association. -1995
- Moyes C., Milne A. Immunogenicity of a recombinant yeast-derived hepatites В vaccine (Engerix-B) in children.// New Zealand Med. J. -1988. -Vol.101. -P. 162−164
- Mutimer D., Dowling D., Cane P. et al. Additive antiviral effects of lamivudine and alfa-interpheron in chronic hepatitis B.// Antivir. Ther. -2000. -Vol.5. -№ 4, -P.273−277
- Mutimer D., Pillay D., Cook P. et al. Selection of multiresistant hepatitis В virus during sequential nucleoside-analogue therapy.// J. Infect. Dis. -2000. -Vol.181. -P.713−716
- Navarro J.F., Teruel J.L., Mateos M.L. et al. Antibody level after hepatitis В vaccination in hemodialysis patients: influence of hepatitis С virus infection.// Am. J. Nephrol. -1996. -Vol.16. -№ 2. -P.95−97
- Ono K., Kashiwagi S. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis В vaccine in haemodialysis patients.// Nephron. -1991. -Vol.58. -P.47−51
- Ozdemir S., Bakkaloglu A., Oran O. Nephrotic syndrome associated with recombinant hepatitis В vaccination: a causal relationship or just a mere association?// Nephrol. Dial. Transplant. -Vol.13. -P. 1888−1889
- Peces R., de la Torre M.R., Urra J.M. Prospective analysis of the influencing the antibody response to hepatitis В vaccine in hemodialysis patients.// Amer. J. Kidney Dis. -1997. -Vol.29. -№ 2. -P.239−245
- Perrillo R.P., Schalm S.W., Schiff E.R. et al. Predictors of HBsAg seroconversion chronic hepatitis В patient treated lamivudine.// Hepatology. -1999. -Vol.30. -317A
- Poorawan Y., Sanpavat S., Pongpunglert W. et al. Protective efficacy of a recombinant DNA hepatites В vaccine in neonates of HBe antigen-positive mothers.//JAMA. -1989. -Vol.261. -P.3278−3287
- Poorawan Y., Suvimol S., Wiroje P. et al. Long-term efficacy of hepatites В vaccine in infants born to hepatitis-Be-antigen-positive mothers.// Pediatr. Infect. Dis. J. -1992. -Vol.11. -P.816−821
- Ramos I., Oliveira J., Alves V. Immunologic and epidemiologic characterization of non-responders/low-responders to hepatitis В vaccine.// Acta Med. Port. -2000. -Vol.13. -№ 4. -P. 159−165
- Regev A., Schiff E.R. Drags therapy for hepatitis B.// Adv. Intern. Med. -2001.-Vol.46. -P. 107−135
- Renzulli G., Gottardello L., Canazza S. et al. Immunogenicity of two hepatitis В vaccines produced by means of recombinant DNA technique.// 35 Congresso Naz. de Igiene (Italy). -1992. -P.l 16−119
- Ring G.H., Lakkis F.G. T lymphocyte-derived cytokines in experimental glomerulonephritis: testing the Thl/Th2 hypothesis.// Nephrol. Dial. Transplant. -1998. -Vol.13. -№ 5. -P.l 101−1103
- Saxena S., Mittal A., Andal A. Pattern of interleukins in minimal-change nephrotic syndrome of childhood.// Nephron. -1993. -Vol.65. -№ 1.- P.56−61
- Scand J. Coutrasting patterns of response to lamivudine monotherapy in chronic hepatitis В patients.// Scand. J. Gastroenterol. -2000. -Vol.2. -Suppl.32. -P.74−78
- Schalm S.W., Heathcote J. Lamivudine and alfa-interferon with chronic hepatitis В infection: a randomised trial.// Gut. -2000. -Vol.46. -№ 4. -P.450−451
- Schalhoub R.J. Pathogenesis of lipoid nephrosis: A disorder of T-cell function.// Lancet. -1974. -#2. -P.556−560
- Schiff E., Cianciara J., Kowdley K. et al. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials.// Hepatology J. -1998. -Vol.28. -163A
- Schnaper H.W. Immunization practices in childhood nephrotic syndrome: a survey of North American pediatric nephrologists.// Pediatr. Nephrol. -1994. Vol.8. -№ 1. -P.4−6
- Simon K., Rotter K., Zalewska M. et al. HBV-DNA level in blood serum as a predictor of good response to therapy with interferon-alpha-2b of patients with chronic hepatitis В.// Med. Sci. Monit. -2000. -Vol.6. -Л1−5. -P.971−975
- Summers J., Mason W. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermidiate.// Cell. -1993. -Vol.29. -P.403−415
- Suranyi M.G., Guasch A., Hall B.M., Myers B.D. Elevated levels of tumor necrosis factor- alfa in the nephrotic syndrome in humans.// Am. J. Kidney Dis. -1993. -Vol.21. -№ 3. -P.251−259
- Tadakoro M. The clinico-patholigical studies of hepatitis В virus nephropathy in adults.// Nippon Jinzo Gakkai. -1999. -Vol.33. -№ 3. -P.257−266
- Teuber G., Lohr H.F., Kallinowski B. Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis В.// Dtsch. Med. Wochenschr. -2001. -Vol.126. -№ 5. -P.97−102
- Topaloglu R., Saatci U., Arikan M. et al. T-cell subsets, interleukin-2 receptor expression and production of interleukin-2 in minimal change nephrotic syndrome.// Pediatr. Nephrol. -1994. -Vol.8. -№ 6. -P.649−652
- Treadvell T.L., Keeffe E.B., Read A. et al. Immunogenicity of two recombinant hepatitis В vaccines in older individuals.// Am. J. Med. -1993. -Vol.95. -P.584−588
- Van Damme P., Tormans G., Beutels P. et al. Hepatitis В prevention in Europe: a preliminary economic evaluation.// Vaccine. -1995. -Vol.13. -Suppl.l. -P.54−57
- Vlassopoulos D., Arvanitis D., Lilis D. et al. Complete success of intradermal vaccination against hepatitis В in advanced chronic renal failure and hemodialysis patients.// Ren. Fail. -1997. -Vol.19. -№ 3. -P.455−460
- Vryheid R.E., Kane M.A., Muller N. et al. Глобальный обзор иммунизации детей и подростков против гепатита В до 1999 года.// Медицина для всех. -2001. -№ 1.-Р.12−15
- Washington D.C., Greenberg D.P., Vadheim С.М. et al. Comparative safety and immunogenicity of two recombinant hepatites В (HBV) vaccines given to infants at 2, 4, 6 month of age.// American Soc. for Microbiology. -1992.-920A
- Watkins S.L., Hogg R.J., Alexander S.R. et al. Response to recombinant hepatitis В (Recombivax HB) vaccine in children with chronic renal failure.// Pediatr. Nephrol. -1995. -Vol.9. -№ 6. -P.72
- Weidermann G., Scheiermann N., Goubau P. et al. Multicenter dose range study of a yeast-derived hepatites В vaccine.// Vaccine. -1987. -Vol.5. -P. 179−183
- Wong D.K., Cheung A.M., O’Rourke K. et al. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positiv chronic hepatitis B. A meta-analysis.// Ann. Intern. Med. -1993. -Vol.119. -P.312−323
- Wood R.C., MacDonald K" Whete K.E. et al. Risk factors for lack of detectable antibody following hepatitis В vaccination of Minnesota health care workers.//J. Am. Med. Ass. -1993. -Vol.270. -P.2935−2939
- Wrzolkowa Т., Zirawska A., Uszycka-Karcz M. et al. Hepatitis В associated glomerulonephritis: electron microscopic studies 98 children.// Am. J. Kidney Des. -1991. -Vol.18. -№ 3. -P.306−312
- Xie J., Wang X., Zhuang G. Relationship between interleukin-2, interleukin-2 receptor and the non- and hypo-responsiveness to hepatitis В vaccine.// Zhonghua Gan Zang Bing Za Zhi. -2000. -Vol.8. -№ 6. -P.332−334
- Xin Yu He, Li J.F., Yue E. Z. et al. In situ hibridization of hepatitis В DNA in hepatitis B-associated glomerulonephritis.// Pediatr. Nephrol. -1998. -Vol.12. -P. 117−120
- Yamabe H. Hepatitis virus and glomerulonephritis.// Intern. Med. -1998. -Vol.37. -№ 10. -P.836−840
- Yao F., Gish R.G. Treatment of chronic hepatitis B: new antiviral therapies.// Curr-Gastroenterol-Rep. -1999. -Vol.1. -Suppl. 1. -P.20−26
- Yap H.K., Cheung W" Murugasu B. et al. Th 1 and Th 2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased 1L-13 mRNA expression in relapse.// J. Am. Soc. Nephrol. -1999. -Vol.10. -№ 3. -P.529−537
- Yuce A., Kpcak N., Ozen H. et al. Prolonged interferon-alpha treatment in children with chronic hepatitis B.// Ann. Trop. Pediatr. -2001. -Vol.12. -№ 1. -P.77−80
- Zang Y., Fang L., Ma X. et al. Hepatitis В virus infection and patogenesis of glomerulonephritis.// Zhongus Bing Li Zue Zhi. -1995. -Vol.24. -№ 6. -P.341−344
- Zhou S.D., Zhang Y.E., Guo M. Y et al. The study of the significance of the appearance of HBeAg in glomerulonephritis.// Chin. J. Nephrol. -1995. -Vol.11. -P. 104−106
- Zhov W.Z., Zhang W.L., Geng L. et al. Glomerulonephropathy associated with hepatitis В virus infection.// Zhonghua Nei Ke Za Zhi. -1990. -Vol.29 -№ 9. -P.530−533
- Zollner В., Petrsen J. 20-fold increase in risk of lamivudine resistance in hepatitis В virus subtipe adw.// Lancet. -2001. -Vol.357. -P.934−935
- Zuckerman A. More then one third of the world’s population has been infected with hepatitis В virus.// Brit. Med. J. -1999. -Vol.318. -№ 7192. -P. 1213